Polyglutamic acid compositions and methods of using
Disclosed herein are compositions comprising one or more polyglutamic acid compounds. The compositions are for treating, ameliorating, preventing, or reducing the symptoms of vaginal dryness and the symptoms associated with menopause. Also described herein are suppository formulations of the compositions.
1. A method for treating vaginal dryness of pre-menopause and post-menopause, maintaining a healthy level of vaginal moisture, or treating and/or ameliorating one or more symptoms of menopause comprising administering a vaginal composition to a subject, wherein the vaginal composition is in the form of a suppository formulation and wherein the suppository formulation comprises one or more polyglutamic acid compounds, a suppository base, and a pharmaceutically acceptable carrier, wherein one of the one or more polyglutamic acid compounds has a molecular weight of 100 kDa and is present in a weight percentage of about 0.01% to about 1% of the total weight of the composition, and wherein the one or more symptoms of menopause are vaginal dryness, vaginal itching, vaginal burning, and/or pain associated with sexual activity.
2. The method of claim 1 , wherein the one or more polyglutamic acid compounds comprises a first polyglutamic acid compound and a second polyglutamic acid compound.
3. The method of claim 2 , wherein the one or more polyglutamic acid compounds further comprises a third polyglutamic acid compound.
4. The method of claim 2 , wherein the first polyglutamic acid compound has an n value that is less than an n value of the second polyglutamic acid compound, wherein the n value is the number of glutamic acid monomers linked together to form each polyglutamic acid compound.
5. The method of claim 3 , wherein the first polyglutamic acid compound has an n value that is less than an n value of the second polyglutamic acid compound, and the third polyglutamic acid compound has an n value that is greater than the n value of the second polyglutamic acid compound, wherein the n value is the number of glutamic acid monomers linked together to form each polyglutamic acid compound.
6. The method of claim 1 , wherein the suppository formulation comprises one or two polyglutamic acid compounds.
7. The method of claim 6 , wherein the suppository formulation further comprises a solubilizer, a humectant, and a surfactant.
8. The method of claim 7 , wherein the amount of the polyglutamic acid compounds, the solubilizer, the humectant, the surfactant, and the suppository bases are in a synergistic ratio by weight.
9. The method of claim 6 , wherein the suppository formulation comprises one polyglutamic acid compound.
10. The method of claim 9 , wherein the suppository formulation further comprises a solubilizer, a humectant, and a surfactant.
11. The method of claim 10 , wherein the solubilizer is water, the humectant is glycerin, the surfactant is polysorbate 80, and the suppository base is saturated fatty acids glycerides C 12 -C 18 .
12. The method of claim 4 , wherein the first polyglutamic acid compound has a molecular weight of 100 kDa and the second polyglutamic acid compound has a molecular weight of 700 kDa.
13. The method of claim 12 , wherein the suppository formulation further comprises a solubilizer, a humectant, and a surfactant.
14. The method of claim 13 , wherein the solubilizer is water, the humectant is glycerin, the surfactant is polysorbate 80, and the suppository base is saturated fatty acids glycerides C 12 -C 18 .
15. The method of claim 1 , wherein the method is for treating the vaginal dryness of pre-menopause and post-menopause, and wherein the suppository formulation is administered to a subject's vaginal cavity.
16. The method of claim 15 , wherein the suppository formulation comprises only one polyglutamic acid compound.
17. The method of claim 15 , wherein the suppository formulation comprises a first polyglutamic acid compound and a second polyglutamic acid compound.
18. The method of claim 1 , wherein the method is for maintaining a healthy level of vaginal moisture, and wherein the suppository formulation is administered to a subject's vaginal tissue.
19. The method of claim 1 , wherein the method is for treating and/or ameliorating one or more symptoms of menopause, and wherein the suppository formulation is administered to a subject's vaginal tissue.
20. A suppository formulation comprising a polyglutamic acid compound, a solubilizer, a humectant, a surfactant, and a suppository base, wherein the amount of the polyglutamic acid, the amount of a solubilizer, the amount of a humectant, the amount of the surfactant, and the amount of the suppository base are in a ratio of 5:396:50:28:1521 by weight, wherein the polyglutamic acid has a molecular weight of 100 kDa, the solubilizer is water, the humectant is glycerin, the surfactant is polysorbate 80, and the suppository base is saturated fatty acids glycerides C 12 -C 18 .
21. The suppository formulation of claim 20 , wherein the suppository formulation disintegrates in the vaginal environment within 30 minutes.
22. A method for treating vaginal dryness of pre-menopause and post-menopause, maintaining a healthy level of vaginal moisture, or treating and/or ameliorating one or more symptoms of menopause comprising administering a vaginal composition to a subject, wherein the vaginal composition is in the form of a suppository formulation and the suppository formulation comprises a first polyglutamic acid compound, a second polyglutamic acid compound, a third polyglutamic acid compound, a suppository base, and a pharmaceutically acceptable carrier, wherein the first polyglutamic acid compound has an n value that is less than an n value of the second polyglutamic acid compound, and the third polyglutamic acid compound has an n value that is greater than the n value of the second polyglutamic acid compound, wherein the n value is the number of glutamic acid monomers linked together to form each polyglutamic acid compound, and wherein the first polyglutamic acid compound has the n value of between about 300 and 500, the second polyglutamic acid compound has the n value between about 1,000 and 10,000, and the third polyglutamic acid compound has the n value between about 20,000 and 30,000, and wherein the one or more symptoms of menopause are vaginal dryness, vaginal itching, vaginal burning, and/or pain associated with sexual activity.